SHORT REPORT

Six novel connexin32 (GJB1) mutations in X-linked Charcot-Marie-Tooth disease


PATIENTS AND METHODS

Patients

Six families with inherited neuropathy were studied. All families originated from the south of England. Ethical approval for genetic studies in neuropathy had been obtained from the National Hospital for Neurology and Neurosurgery Ethics Committee.

Table 1 presents the clinical and electrophysiological details. All index cases of the disease had been diagnosed as probable CMT based on typical clinical features of distal wasting, weakness, sensory disturbance, hyporeflexia, and foot deformities. The median motor nerve conduction velocity was often less than 38 m/s in the median nerve (a value used to distinguish between “demyelinating” and “axonal” forms of CMT), but in female patients it may be faster than this or normal. Mutation of the GJB1 gene is responsible for the majority of CMTX cases. This report describes six British CMTX families with novel mutations (four missense, one nonsense, and one frame shift) of the GJB1 gene. Affected members in these families had typical signs of CMT but in some affected members of three families there was additional central nervous system involvement or deafness in the absence of any other explanation other than CMT.

METHODS

DNA was extracted from leucocytes using a standard phenol-chloroform method.10 The coding region of the GJB1 gene was amplified using primers reported by Bergoffen et al.11 The annealing temperature for polymerase chain reaction was 56°C to 53°C in a touch down protocol (that is, reduced 0.1°C per cycle) for 25 cycles and then was held constant at 53°C for 12 cycles. The sequencing reactions were carried out using the polymerase chain reaction primers and BigDye Terminator cycle sequencing chemistry (Applied Biosystems, Foster City, California, USA). Sequences were analysed on an ABI377 automated DNA sequencer (Applied Biosystems).

RESULTS

Direct sequencing of the GJB1 gene in these six patients identified six novel mutations. As table 1 shows, the six mutations were four missense, one nonsense, and one frame shift mutation. Both W24C (missense) and T55R (missense) are highly conserved amino acids among GJB1 and other gap junction protein sequences (such as GJB3 and GJB4) in Xenopus laevis, chicken, and all mammals. V125D (missense) and F153S (missense) are also highly conserved in the GJB1 proteins among all mammalian species. These mutations were not present in 50 normal controls. In families 1, 3, and 5, DNA

Abbreviations: CMT, Charcot-Marie-Tooth disease; CMTX, X-linked Charcot-Marie-Tooth disease; CNS, central nervous system; GJB1, gap junction protein β1; MCV, motor nerve conduction velocity; MRI, magnetic resonance image
from other affected members was available and the appropriate mutation was confirmed in each affected patient. Clinically, the affected patients were similar to previously described patients with CMT who had GJB1 mutations, with a predominantly distal motor and sensory neuropathy in most patients (table 1). Males were more severely clinically affected and had slower MCVs than females. Interestingly, affected members from four families had CNS involvement or deafness, as has been previously described with GJB1 mutations.

In family 1, one affected female (patient 1, table 1) had bilateral extensor plantars but this was probably explained by a second diagnosis of spastic diplegia secondary to prematurity. In family 2, patient 4 had deafness and abnormal auditory brainstem potentials. In family 6, patient 12 also had deafness and extensor plantars with no other explanation other than CMT. Patient 5, family 3 had an interesting magnetic resonance image (MRI) of the brain (fig 1) with mild but definitely abnormal white matter high signal lesions for her age without any other explanation other than CMT.}

**DISCUSSION**

CMTX is a common cause of inherited neuropathy. We report six novel mutations of the GJB1 gene from six British CMTX families. The disease onset of the six index patients was usually in later childhood or adolescence with one notable exception. Patient 7, family 3 was noted to have difficulty walking at age 15 months but did not have abnormal sensory or motor findings. At age three years and 10 months his reflexes were present but by age five and a half he was clinically affected with absent reflexes and high arched feet. He tolerated only limited nerve conduction studies at age five but his ulnar MCV at this stage was 49 m/s. Similarly, patient 9, family 5 was definitely affected but his ulnar MCV at age 12 was 51 m/s. It was not available.

The clinical features of the neuropathy in our patients were similar to those described previously in patients with GJB1 mutations. The disease was usually more severe in males than in females. Electrophysiological findings, including slowing of median and ulnar nerve conduction velocities, were more severe in males than in females. In our patients, patients had normal ankle jerks with other studies.

Table 1: Clinical manifestations and electrophysiological studies of the families with gap junction protein β1 (GJB1) mutations

<table>
<thead>
<tr>
<th>Family</th>
<th>Mutation</th>
<th>Patient</th>
<th>Age at onset (years)</th>
<th>Sex/age (years)</th>
<th>Muscle wasting (upper/lower)</th>
<th>Sensory disturbance</th>
<th>Tendon reflex</th>
<th>CNS involvement</th>
<th>Electrophysiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>W24C</td>
<td>1</td>
<td>15</td>
<td>F/30</td>
<td>D&gt;P, +/+</td>
<td>Large fibre, mild</td>
<td>Hyporeflexia</td>
<td>Extensor plantar response</td>
<td>Ulnar MCV (m/s) DML (ms)</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>11</td>
<td>F/28</td>
<td>D&gt;P, +/+</td>
<td>Large fibre, mild</td>
<td>Absent</td>
<td></td>
<td></td>
<td>53/2.7</td>
</tr>
<tr>
<td></td>
<td>12*</td>
<td>M/66</td>
<td>D&gt;P, ++++/+++</td>
<td>Both, severe</td>
<td>Areflexia</td>
<td>Deafness and abnormal auditory brainstem potentials</td>
<td>Brain MRI: high signal in the cerebral hemisphere and right mid brain in T2WI</td>
<td>24/3.6</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>TSSR</td>
<td>4</td>
<td>16*</td>
<td>M/71</td>
<td>D&gt;P, ++++/+++</td>
<td>Both, moderate</td>
<td>Areflexia</td>
<td>Brain MRI: high signal in the cerebral hemisphere and right mid brain in T2WI</td>
<td>33/4.9</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>E109Stop</td>
<td>25</td>
<td>F/33</td>
<td>D&gt;P, ++++/+++</td>
<td>Large fibre, mild</td>
<td>Areflexia</td>
<td></td>
<td>49/3.8</td>
</tr>
<tr>
<td>6</td>
<td>V125D</td>
<td>6</td>
<td>4*</td>
<td>M/12</td>
<td>D&gt;P, +/+</td>
<td>No</td>
<td>Areflexia</td>
<td>Brain MRI: high signal in the cerebral hemisphere and right mid brain in T2WI</td>
<td>37/3.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7</td>
<td>15 months</td>
<td>M/5</td>
<td>D&gt;P, +/+</td>
<td>No</td>
<td>Areflexia</td>
<td>Brain MRI: high signal in the cerebral hemisphere and right mid brain in T2WI</td>
<td>49/2.3</td>
</tr>
<tr>
<td>5</td>
<td>F153S</td>
<td>9</td>
<td>9*</td>
<td>M/12</td>
<td>D&gt;P, ±/+</td>
<td>Asymptomatic</td>
<td>Normal, brisk AJ</td>
<td></td>
<td>37/4.5</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td></td>
<td>F/42</td>
<td>D&gt;P, ++/+++</td>
<td>Asymptomatic</td>
<td>Normal, brisk AJ</td>
<td>Normal, brisk AJ</td>
<td></td>
<td>51/2.9</td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>12</td>
<td>M/52</td>
<td>D&gt;P, +/++</td>
<td>Asymptomatic</td>
<td>Normal, brisk AJ</td>
<td>Normal, brisk AJ</td>
<td></td>
<td>55/2.6</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>16*</td>
<td>M/54</td>
<td>D&gt;P, ++++/+++</td>
<td>Large fibre, mild, small fibre, moderate</td>
<td>Areflexia</td>
<td>Deafness and extensor plantar response</td>
<td>Brain MRI: high signal in the cerebral hemisphere and right mid brain in T2WI</td>
<td>44/7.3</td>
</tr>
</tbody>
</table>

†, minimal; +, mild; ++, moderate; ++++, severe; AJ, ankle jerks; CMAP, compound motor action potentials; CNS, central nervous system; D, distal; DML, distal motor latency; F, female; Fs, frame shift; M, male; MCV, motor conduction velocity; MRI, magnetic resonance image; P, proximal; SAP, sensory action potential; T2WI, T2 weighted image. *Index case.

**Figure 1** Magnetic resonance image of the brain of patient 5, family 3. There are non-specific but definitely pathological white matter lesions (arrows).
with CMTX,\(^6\)\(^1\)\(^3\)\(^4\) but obviously the patient numbers in our study and particularly the numbers with each mutation are too small to discuss either the prevalence of CNS findings with GJB1 mutations or the specificity of CNS findings with particular mutations. It is interesting that GJB1 is expressed in the CNS in oligodendrocytes and other neuronal populations.\(^6\) The MRI findings in patient 5, family 3 are of interest, particularly because she is female. Although the white matter lesions are considered definitely pathological for her age, they are non-specific. Similar MRI findings have been rarely reported with GJB1 mutations\(^5\)\(^6\)\(^6\) but the relation of these changes to GJB1 mutations has not been established. The findings in our patient are minimal and non-specific but it is of interest that the CNS manifestations in patients with GJB1 mutations are usually mild. It would be of interest to see whether these non-specific but pathological findings are found more frequently in both male and female patients with CMTX with GJB1 mutations.

In conclusion, we describe six novel GJB1 mutations in patients with CMTX. CMTX secondary to GJB1 mutations is now the second commonest cause of CMT. GJB1 should be the first gene screened for mutations in all CMT type 1 families who are negative for the chromosome 17p11.2 duplication and who have no male to male transmission. This is particularly important in families where males are more severely affected than females, especially if the electrophysiological data suggest that males have MCVs in the demyelinating or intermediate range and females have MCVs in the axonal range, and where there is associated CNS disease. Finally, it is appropriate to consider screening for GJB1 mutations in sporadic cases, where the length of the history or the presence of foot deformity raises the possibility of CMT and especially if the chromosome 17p11.2 duplication is negative.

ACKNOWLEDGEMENTS

We thank all patients participating in this study. The work was supported by the Brain Research Trust.

Authors’ affiliations

M-J Lee, I Nelson, H Houlden, M G Sweeney, N W Wood, M M Reilly, Department of Molecular Pathogenesis, Institute of Neurology, Queen Square, London WC1N 3BG, UK
D Hilton-Jones, Department of Neurology, The Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
J Blake, Department of Neuropsychology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK

Competing interests: none declared

Correspondence to: Dr M M Reilly, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG; M.Reilly@ion.ucl.ac.uk

Received 8 January 2002
In revised form 5 April 2002
Accepted 22 April 2002

REFERENCES